Comparison of effect of preoperative dienogest and gonadotropin-releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas
Autor: | Rie Ozaki, Keisuke Murakami, Jun Kumakiri, Yu Kawasaki, Mari Kitade, Makoto Jinushi, Shinichiro Ikuma |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Laparoscopic surgery medicine.medical_specialty Adolescent medicine.drug_class medicine.medical_treatment Endometriosis Urology Cystectomy Contraceptives Oral Hormonal Gonadotropin-Releasing Hormone Young Adult 03 medical and health sciences chemistry.chemical_compound Hormone Antagonists 0302 clinical medicine Gonadotropin-releasing hormone agonist medicine Humans Nandrolone Prospective Studies Adverse effect 030219 obstetrics & reproductive medicine business.industry Obstetrics and Gynecology Metrorrhagia General Medicine Middle Aged medicine.disease Dienogest chemistry Tolerability 030220 oncology & carcinogenesis Preoperative Period Hormonal therapy Female Laparoscopy medicine.symptom business |
Zdroj: | Archives of Gynecology and Obstetrics. 302:969-976 |
ISSN: | 1432-0711 0932-0067 |
Popis: | To compare the effects of preoperative dienogest (DNG) and gonadotropin-releasing hormone (GnRH) agonist administration on the improvement of preoperative symptoms and surgical outcomes in patients who underwent laparoscopic cystectomy for ovarian endometriomas. Seventy patients who were scheduled for laparoscopic surgery were enrolled in the study. They were divided into two groups: 35 patients who received DNG for 4 months preoperatively (group D) and 35 patients who received low-dose sustained-release goserelin acetate for 4 months preoperatively (group G). Preoperative outcomes, including pain score associated with endometriosis, using the numerical rating scale (NRS), adverse events of hormonal therapy and Kupperman index (KI) before and after treatment, surgical outcomes including total surgical duration and blood loss, and postoperative recurrence of endometrioma were compared between the two groups. Regarding preoperative symptoms, NRS and KI at 4 months after preoperative hormonal therapy were significantly lower in group D than in group G (NRS, 5.3 ± 5.5 vs. 2.7 ± 3.9; P = 0.01; KI, 16.0 ± 11.0 vs. 9.2 ± 7.6; P = 0.006). Regarding adverse events, the incidence of hot flashes was significantly lower in group D than in group G (P |
Databáze: | OpenAIRE |
Externí odkaz: |